The efficacy of coronary sinus reducer in patients with refractory angina-A systematic review of the literature
| Autor: | Tong Liu, Panagiotis Kitsoulis, Costas Tsioufis, Gary Tse, Adrian Baranchuk, Antonios Sideris, Emmanouil S. Brilakis, Stavros Stavrakis, George Bazoukis, Konstantinos P. Letsas |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment 030204 cardiovascular system & hematology Cochrane Library Revascularization law.invention Angina Pectoris Angina Coronary artery disease 03 medical and health sciences Blood Vessel Prosthesis Implantation 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Radiology Nuclear Medicine and imaging 030212 general & internal medicine Coronary sinus Aged Reducer business.industry Endovascular Procedures Coronary Sinus Canadian Cardiovascular Society Middle Aged medicine.disease Blood Vessel Prosthesis Treatment Outcome Cardiology Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of interventional cardiology. 31(6) |
| ISSN: | 1540-8183 |
| Popis: | Objectives The aim of our systematic review was to investigate the efficacy of coronary sinus (CS) reducer device in patients with refractory angina. Background The CS reducer device provides a therapeutic option for patients with coronary artery disease who are not suitable for revascularization. Methods Two independent investigators (GB and GT) systematically searched the Medline and Cochrane library databases for studies describing the efficacy and safety of the CS reducer in patients with refractory angina from January 1, 2000 until May 12, 2018 using the following terms: "coronary sinus (reducer OR reducing) device." Efficacy was defined as ≥1 unit improvement in the Canadian cardiovascular society (CCS) score. Results Our search strategy provided six studies (five observational studies and one randomized clinical trial) with 196 patients. The CS reducer device was effective in 146/186 (78.5%) patients. CCS score improved from 3.2 at baseline to 1.9 after 8.6 months of follow-up. The efficacy of CS reducer device was also demonstrated as an improvement in Seattle Angina Questionnaire score, dobutamine echocardiography, thalium single-photon emission computed tomography perfusion studies, 6-min-walk test and myocardial perfusion reserve index. Implantation failed in 4 of 196 (2%) patients and 5 patients (2.5%) had a complication during 30-day follow-up. Conclusions The CS reducer is a promising treatment option for patients with refractory angina who are not candidates for revascularization. However, larger randomized control trials with long-term follow-up are needed to elucidate its role. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |